Loading

CureVac NV

June 16, 2025
Company Presentation
Oncology
We are pioneering the development of a completely new class of drugs based on the messenger RNA (mRNA). The basic principle is the use of this molecule as a data carrier for information, with the help of which the body itself can produce its own active substances to combat various diseases. It all began with an unexpected discovery. CureVac’s founder, Dr. Ingmar Hoerr (a doctoral student at the time), discovered that when it was administered directly into tissue, the historically unstable biomolecule mRNA could be used as a therapeutic vaccine or agent after optimization—no complicated reformulations or molecular packaging needed. With a single discovery, CureVac opened the world up to the potential of mRNA to treat diseases and create vaccines. Officially founded in 2000, CureVac is the world’s first company to successfully harness mRNA for medical purposes—because we saw opportunities where others saw obstacles.
CureVac NV
Company HQ City: Tuebingen
Company HQ State: Tuebingen
Company HQ Country: Germany
Year Founded: 2000
Lead Product in Development: mRNA Vaccines

CEO

Alexander Zehnder, MD

Year Founded

2000

Development Phase of Lead Product

Phase I

Number of Unlicensed Products Looking for Licensing

4+

Exchange

NASDAQ

Ticker

CVAC

When you expect your next catalyst update?

Phase I readout, IND filing for programs, litigation updates,

What is your next catalyst (value inflection) update?

2H 2025

Website

https://www.curevac.com/en/
Primary Speaker
Thaminda Ramanayake
Thaminda Ramanayake, MBA
Chief Business Officer
CureVac NV

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS